Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat to Pfizer’s fast-selling bladder cancer drug.

Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...

The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, which has invested heavily in cell and gene therapy technology.

Xenon shares skyrocketed nearly 50% on results that handily beat Wall Street expectations. Elsewhere, Capricor got a decision date for a spurned cell therapy and AbbVie and Regeneron showcased obesity ...

The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a key CDC panel ...

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.